A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease.
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2016
At a glance
- Drugs RPh 201 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Regenera Pharma
- 05 Dec 2016 Status changed from recruiting to completed.
- 23 Dec 2014 Planned End Date changed from 1 Feb 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov .
- 07 Dec 2012 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.